When you consider all lung diseases together, they’re the third biggest killer in the United States. That’s why, at INC Research, we are dedicated to helping you get respiratory medicine to the people who need it, sooner.
We have a dedicated Respiratory Disease group and clinical operations team with years of experience working on respiratory trials. They know more about recruiting patients with respiratory disorders than anyone else. And with our extensive therapeutic and regulatory experience across the broad spectrum of indications, you can be confident that your product will get the care and attention it deserves.
Our respiratory disease study experience includes:
  • Allergy
  • Asthma
  • COPD
  • Cystic fibrosis
  • Lower respiratory tract infections
  • Lung cancer
  • Pulmonary arterial hypertension
  • Smoking cessation
  • Upper respiratory tract infections

Our work in practice


One Phase II and five Phase III studies for a fixed ICS-LABA combination product requiring more than 2,000 adults and adolescents with asthma across 339 sites in 12 countries.


We developed and executed a robust global operational plan and patient recruitment strategy, combining the multiple studies into one program, to combat the studies’ strict inclusion criteria and worldwide breadth.


We screened 4,500 subjects and randomized 2,300 over a 17-month period, enabling our customer to submit their NDA to the FDA three months ahead of schedule.


We are a market-leading CRO whose dedicated team has years of experience working on respiratory clinical trials.  


http://www.hopkinsmedicine.org/healthlibrary/conditions/cardiovascular_diseases/vital_signs_body_temperature_pulse_rate_respiration_rate_blood_pressure_85,P00866/ Accessed June 13 2016.

a This is an estimate of INC Research studies from the last five years that are completed or scheduled to complete for this therapy area.